Literature DB >> 33495929

Opicapone-induced reversible myopathy in a patient with advanced Parkinson's disease and familial hyperCKemia.

Maurizio Morelli1,2, Andrea Quattrone1, Stefania Barone1, Federico Tosto1, Antonio Gambardella1,2, Aldo Quattrone3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33495929     DOI： 10.1007/s10072-021-05071-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  4 in total

Review 1.  Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.

Authors:  Margherita Fabbri; Joaquim J Ferreira; Andrew Lees; Fabrizio Stocchi; Werner Poewe; Eduardo Tolosa; Olivier Rascol
Journal:  Mov Disord       Date:  2018-09-27       Impact factor: 10.338

Review 2.  High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm.

Authors:  L Morandi; C Angelini; A Prelle; A Pini; B Grassi; G Bernardi; L Politano; C Bruno; D De Grandis; P Cudia; A Citterio
Journal:  Neurol Sci       Date:  2006-11       Impact factor: 3.307

3.  Safety Profile of Opicapone in the Management of Parkinson's Disease.

Authors:  Andrew Lees; Joaquim J Ferreira; José-Francisco Rocha; Olivier Rascol; Werner Poewe; Helena Gama; Patrício Soares-da-Silva
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

4.  Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia.

Authors:  I Carbone; C Bruno; F Sotgia; M Bado; P Broda; E Masetti; A Panella; F Zara; F D Bricarelli; G Cordone; M P Lisanti; C Minetti
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.